Expert Opinion on Investigational Drugs, Volume 28, Issue 10 (2019)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 28, Issue 10 (2019)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Volume 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Drug Evaluation

Article
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma
Bradley A McGregor & Guru Sonpavde
Pages: 821-826
Published online: 17 Sep 2019
AbstractforEnfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma | Full Text | References | PDF (571.3 KB) | EPUB
  • 1252 Views
  • 19 CrossRef citations
  • 0Altmetric
Article
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
Mario Cazzola, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera
Pages: 827-833
Published online: 01 Sep 2019
AbstractforEnsifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD | Full Text | References | PDF (785.4 KB) | EPUB
  • 698 Views
  • 25 CrossRef citations
  • 0Altmetric
Article
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia
Georgina S. Daher-Reyes, Brayan M. Merchan & Karen W. L. Yee
Pages: 835-849
Published online: 19 Sep 2019
AbstractforGuadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Full Text | References | PDF (1.1 MB) | EPUB
  • 557 Views
  • 38 CrossRef citations
  • 0Altmetric

Review

Review
Investigational MET inhibitors to treat Renal cell carcinoma
Lakshminarayanan Nandagopal, Guru P. Sonpavde & Neeraj Agarwal
Pages: 851-860
Published online: 03 Oct 2019
AbstractforInvestigational MET inhibitors to treat Renal cell carcinoma | Full Text | References | PDF (993.9 KB) | EPUB
  • 362 Views
  • 15 CrossRef citations
  • 0Altmetric
Review
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
Rehan M. Hussain, Ashley E. Neiweem, Viral Kansara, Alon Harris & Thomas A. Ciulla
Pages: 861-869
Published online: 26 Sep 2019
AbstractforTie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease | Full Text | References | PDF (912.1 KB) | EPUB
  • 2051 Views
  • 69 CrossRef citations
  • 0Altmetric
Review
Drugs under development for the treatment of functional dyspepsia and related disorders
Jan Tack, Imke Masuy, Karen Van Den Houte, Lucas Wauters, Jolien Schol, Tim Vanuytsel, Alain Vandenberghe & Florencia Carbone
Pages: 871-889
Published online: 08 Oct 2019
AbstractforDrugs under development for the treatment of functional dyspepsia and related disorders | Full Text | References | PDF (1.5 MB) | EPUB
  • 336 Views
  • 15 CrossRef citations
  • 0Altmetric
Review
Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency
Anita Pye & Alice M Turner
Pages: 891-902
Published online: 11 Oct 2019
AbstractforExperimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency | Full Text | References | PDF (1,016.1 KB) | EPUB
  • 558 Views
  • 13 CrossRef citations
  • 0Altmetric
Review
Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
Dan Wang, Li Yang, Weina Yu & Yi Zhang
Pages: 903-916
Published online: 04 Oct 2019
AbstractforInvestigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors | Full Text | References | PDF (1.3 MB) | EPUB
  • 209 Views
  • 4 CrossRef citations
  • 0Altmetric
Review
Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors
Leyuan Chen, Yuqing Duan, Huiqiang Wei, Hongxin Ning, Changfen Bi, Ying Zhao, Yong Qin & Yiliang Li
Pages: 917-930
Published online: 29 Aug 2019
AbstractforAcetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors | Full Text | References | PDF (1.7 MB) | EPUB
  • 2050 Views
  • 66 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy
Ava Aghakhani et al.
Review Article | Published online: 30 May 2024
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus
Eric F. Morand et al.
Plain Language Summary of Publication | Published online: 29 May 2024
Open Access
Inflammation and Huntington’s disease – a neglected therapeutic target?
Sophie E. Field et al.
Review Article | Published online: 29 May 2024
Open Access
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration
Shogo Hashimoto et al.
Review Article | Published online: 29 May 2024
View all latest articles